Combinatorial in silico and in vivo evaluation of immune response elicitation by the affibody ZHER2

Siavoshinia, Leila; Kheirollah, Alireza; Zeinali, Majid; Barzegari, Ebrahim; Jamalan, Mostafa

doi:10.1016/j.intimp.2021.108368

Cited by 1 publication

(2 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous study, a powerful photo‐activating anti‐HER2 AMDC was developed by combining a high‐affinity anti‐HER2 antibody–mimetic, Z HER2:342 , 14 fused to Cupid, with Psyche binding to Ax‐SiPc. Z HER2:342 and Cupid were not antigenic in primates 12,15 . Furthermore, this drug showed a marked tumor‐reducing effect against KPL‐4 xenografts, a human HER2‐expressed breast cancer cell line, without side effects 11 .…”

Section: Introductionmentioning

confidence: 99%

“…Z HER2:342 and Cupid were not antigenic in primates. 12 , 15 Furthermore, this drug showed a marked tumor‐reducing effect against KPL‐4 xenografts, a human HER2‐expressed breast cancer cell line, without side effects. 11 However, pathological analysis after the initial treatment indicated that some animals had malignant cells in their remains.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pathological complete remission of relapsed tumor by photo‐activating antibody–mimetic drug conjugate treatment

et al. 2022

View full text Add to dashboard Cite

Antibody–mimetic drug conjugate is a novel noncovalent conjugate consisting of an antibody‐mimetic recognizing a target molecule on the cancer cell surface and low‐molecular‐weight payloads that kill the cancer cells. In this study, the efficacy of a photo‐activating antibody–mimetic drug conjugate targeting HER2‐expressing tumors was evaluated in mice, by using the affibody that recognize HER2 (ZHER2:342) as a target molecule and an axially substituted silicon phthalocyanine (a novel potent photo‐activating compound) as a payload. The first treatment with the photo‐activating antibody–mimetic drug conjugates reduced the size of all HER2‐expressing KPL‐4 xenograft tumors macroscopically. However, during the observation period, relapsed tumors gradually appeared in approximately 50% of the animals. To evaluate the efficacy of repeated antibody–mimetic drug conjugate treatment, animals with relapsed tumors were treated again with the same regimen. After the second observation period, the mouse tissues were examined histopathologically. Unexpectedly, all relapsed tumors were eradicated, and all animals were diagnosed with pathological complete remission. After the second treatment, skin wounds healed rapidly, and no significant side effects were observed in other organs, except for occasional microscopic granulomatous tissues beneath the serosa of the liver in a few mice. Repeated treatments seemed to be well tolerated. These results indicate the promising efficacy of the repeated photo‐activating antibody–mimetic drug conjugate treatment against HER2‐expressing tumors.

show abstract

Section: Introductionmentioning

confidence: 99%